Top Ten Videos to watch

HISTORY Brings 'Roots' Cast And Crew To The White House For Screening
Graduates tossing caps into the air
Freddie Gray Baltimore Protests
Mid section of man in graduation gown holding diploma
Legendary Baseball Player Tony Gwynn's Family Files A Lawsuit Against Big Tobacco
ME.jailhouse#2.0117.CW Montebello City Council has approved use of a private contractor to run the n
Chicago Mayor Rahm Emanuel Addresses Police Misconduct At Chicago City Council Meeting
WWII Soldiers Standing In A Flag Draped Sunset - SIlhouette
Students Taking a College Exam
Bill Cosby Preliminary Hearing
Hillary Clinton Campaigns In Louisville, Kentucky
Worried black businesswoman at desk
Tyler Perry And Soledad O'Brien Host Gala Honoring Bishop T.D. Jakes' 35 Years Of Ministry
Teacher with group of preschoolers sitting at table
FBI Officials Discuss Apprehension Of Explosions Suspect After Three-Day Manhunt
NFC Championship - San Francisco 49ers v Atlanta Falcons
Protests Erupt In Chicago After Video Of Police Shooting Of Teen Is Released
Nine Dead After Church Shooting In Charleston
Portrait of senior African woman holding money
President Bush Speals At Federalist Society's Gala
Police Line Tape
Senior Woman's Hands
Police officers running
New Orleans Residents Return to Housing Projects
David Banner
Leave a comment

European Union regulators approved Merck & Co.’s hepatitis C drug Victrelis, the company said Monday.

The ruling allows Merck to market Victrelis in all 27 European Union countries. Victrelis is a pill taken three times per day, and it blocks an enzyme that helps the hepatitis C virus reproduce.

It was approved for use in combination with standard drugs in patients who are untreated or have failed on other treatments. Victrelis is given with Roche’s injected hepatitis C drug Pegasys and ribavirin pills.

U.S. regulators approved Victrelis on May 13.

Shares of Merck dropped 60 cents, or 1.7 percent, to $35.33 in afternoon trading amid a broad market retreat.

Also On News One: